The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways

Cancer Letters

Volumn 338, Issue 2, 2013, Pages 292-299

  Banerjee, Pallavi ^a,b   Basu, Aninda ^a,b   Arbiser, Jack L ^c   Pal, Soumitro ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HO 1; Honokiol; Ras; Renal tumor; VEGF

Indexed keywords

CALCINEURIN INHIBITOR; HEME OXYGENASE 1; HONOKIOL; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RAF PROTEIN; RAS PROTEIN; TRANSCRIPTION FACTOR NRF2; VASCULOTROPIN;

APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

HO-1; HONOKIOL; RAS; RENAL TUMOR; VEGF;

APOPTOSIS; BIPHENYL COMPOUNDS; CALCINEURIN; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOSPORINE; DOWN-REGULATION; GENE EXPRESSION REGULATION; GENES, RAS; HEME OXYGENASE-1; HUMANS; KIDNEY NEOPLASMS; LIGNANS; PHOSPHORYLATION; RAF KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84881666962     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.036     Document Type: Article

References (42)

1. Kasiske B.L., Snyder J.J., Gilbertson D.T., Wang C. Cancer after kidney transplantation in the United States. Am. J. Transplant. 2004, 4:905-913.
2. Bustami R.T., Ojo A.O., Wolfe R.A., Merion R.M., Bennett W.M., McDiarmid S.V., Leichtman A.B., Held P.J., Port F.K. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am. J. Transplant. 2004, 4:87-93.
3. Wimmer C.D., Rentsch M., Crispin A., Illner W.D., Arbogast H., Graeb C., Jauch K.W., Guba M. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007, 71:1271-1278.
4. Hojo M., Morimoto T., Maluccio M., Asano T., Morimoto K., Lagman M., Shimbo T., Suthanthiran M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397:530-534.
5. Guba M., Graeb C., Jauch K.W., Geissler E.K. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation 2004, 77:1777-1782.
6. Basu A., Contreras A.G., Datta D., Flynn E., Zeng L., Cohen H.T., Briscoe D.M., Pal S. Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res. 2008, 68:5689-5698.
7. Datta D., Contreras A.G., Basu A., Dormond O., Flynn E., Briscoe D.M., Pal S. Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells. Cancer Res. 2009, 69:8902-8909.
8. Liu J., Farmer J.D., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991, 66:807-815.
9. Yarosh D.B., Pena A.V., Nay S.L., Canning M.T., Brown D.A. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J. Invest. Dermatol. 2005, 125:1020-1025.
10. Basu A., Banerjee P., Contreras A.G., Flynn E., Pal S. Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40. PLoS One 2011, 6:e23919.
11. Crespo P., Xu N., Simonds W.F., Gutkind J.S. Ras-dependent activation of MAP kinase pathway mediated by G-protein beta gamma subunits. Nature 1994, 369:418-420.
12. Oka H., Chatani Y., Hoshino R., Ogawa O., Kakehi Y., Terachi T., Okada Y., Kawaichi M., Kohno M., Yoshida O. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 1995, 55:4182-4187.
13. Banerjee P., Basu A., Datta D., Gasser M., Waaga-Gasser A.M., Pal S. The heme oxygenase-1 protein is overexpressed in human renal cancer cells following activation of the Ras-Raf-ERK pathway and mediates anti-apoptotic signal. J. Biol. Chem. 2011, 286:33580-33590.
14. Banerjee P., Basu A., Wegiel B., Otterbein L.E., Mizumura K., Gasser M., Waaga-Gasser A.M., Choi A.M., Pal S. Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules. J. Biol. Chem. 2012, 287:32113-32123.
15. Dulak J., Deshane J., Jozkowicz A., Agarwal A. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 2008, 117:231-241.
16. Costa L.J., Drabkin H.A. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007, 12:1404-1415.
17. Fujita M., Itokawa H., Sashida Y. Studies on the components of Magnolia obovata Thunb. 3. Occurrence of magnolol and honokiol in M. obovata and other allied plants. Yakugaku Zasshi 1973, 93:429-434.
18. Liou K.T., Shen Y.C., Chen C.F., Tsao C.M., Tsai S.K. The anti-inflammatory effect of honokiol on neutrophils: mechanisms in the inhibition of reactive oxygen species production. Eur. J. Pharmacol. 2003, 475:19-27.
19. Hibasami H., Achiwa Y., Katsuzaki H., Imai K., Yoshioka K., Nakanishi K., Ishii Y., Hasegawa M., Komiya T. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells. Int. J. Mol. Med. 1998, 2:671-673.
20. Konoshima T., Kozuka M., Tokuda H., Nishino H., Iwashima A., Haruna M., Ito K., Tanabe M. Studies on inhibitors of skin tumor promotion, IX. Neolignans from Magnolia officinalis. J. Nat. Prod. 1991, 54:816-822.
21. Fried L.E., Arbiser J.L. Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid. Redox Signal 2009, 11:1139-1148.
22. Bai X., Cerimele F., Ushio-Fukai M., Waqas M., Campbell P.M., Govindarajan B., Der C.J., Battle T., Frank D.A., Ye K., Murad E., Dubiel W., Soff G., Arbiser J.L. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J. Biol. Chem. 2003, 278:35501-35507.
23. Hahm E.R., Arlotti J.A., Marynowski S.W., Singh S.V. Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction. Clin. Cancer Res. 2008, 14:1248-1257.
24. Battle T.E., Arbiser J., Frank D.A. The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells. Blood 2005, 106:690-697.
25. Ishitsuka K., Hideshima T., Hamasaki M., Raje N., Kumar S., Hideshima H., Shiraishi N., Yasui H., Roccaro A.M., Richardson P., Podar K., Le Gouill S., Chauhan D., Tamura K., Arbiser J., Anderson K.C. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood 2005, 106:1794-1800.
26. Garcia A., Zheng Y., Zhao C., Toschi A., Fan J., Shraibman N., Brown H.A., Bar-Sagi D., Foster D.A., Arbiser J.L. Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin. Cancer Res. 2008, 14:4267-4274.
27. Li L., Han W., Gu Y., Qiu S., Lu Q., Jin J., Luo J., Hu X. Honokiol induces a necrotic cell death through the mitochondrial permeability transition pore. Cancer Res. 2007, 67:4894-4903.
28. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 1995, 146:1029-1039.
29. Yeung K., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., Fee F., Katsanakis K.D., Rose D.W., Mischak H., Sedivy J.M., Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999, 401:173-177.
30. Hagan S., Garcia R., Dhillon A., Kolch W. Raf kinase inhibitor protein regulation of raf and MAPK signaling. Methods Enzymol. 2006, 407:248-259.
31. Ryter S.W., Choi A.M. Heme oxygenase-1: molecular mechanisms of gene expression in oxygen-related stress. Antioxid. Redox Signal 2002, 4:625-632.
32. Kivela A.M., Kansanen E., Jyrkkanen H.K., Nurmi T., Yla-Herttuala S., Levonen A.L. Enterolactone induces heme oxygenase-1 expression through nuclear factor-E2-related factor 2 activation in endothelial cells. J. Nutr. 2008, 138:1263-1268.
33. Walter D.H., Haendeler J., Galle J., Zeiher A.M., Dimmeler S. Cyclosporin A inhibits apoptosis of human endothelial cells by preventing release of cytochrome C from mitochondria. Circulation 1998, 98:1153-1157.
34. Pritchard D.E., Singh J., Carlisle D.L., Patierno S.R. Cyclosporin A inhibits chromium(VI)-induced apoptosis and mitochondrial cytochrome c release and restores clonogenic survival in CHO cells. Carcinogenesis 2000, 21:2027-2033.
35. Yu C., Zhang Q., Zhang H.Y., Zhang X., Huo X., Cheng E., Wang D.H., Arbiser J.L., Spechler S.J., Souza R.F. Targeting the intrinsic inflammatory pathway: honokiol exerts proapoptotic effects through STAT3 inhibition in transformed Barrett's cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303:G561-G569.
36. Munroe M.E., Arbiser J.L., Bishop G.A. Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J. Immunol. 2007, 179:753-763.
37. Finley D.S., Pantuck A.J., Belldegrun A.S. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011, 16(Suppl. 2):4-13.
38. Matallanas D., Birtwistle M., Romano D., Zebisch A., Rauch J., von Kriegsheim A., Kolch W. Raf family kinases: old dogs have learned new tricks. Genes Cancer 2011, 2:232-260.
39. Corbit K.C., Trakul N., Eves E.M., Diaz B., Marshall M., Rosner M.R. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J. Biol. Chem. 2003, 278:13061-13068.
40. Nath K.A. Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. Kidney Int. 2006, 70:432-443.
41. Alaoui-Jamali M.A., Bismar T.A., Gupta A., Szarek W.A., Su J., Song W., Xu Y., Xu B., Liu G., Vlahakis J.Z., Roman G., Jiao J., Schipper H.M. A novel experimental heme oxygenase-1-targeted therapy for hormone-refractory prostate cancer. Cancer Res. 2009, 69:8017-8024.
42. Jozkowicz A., Was H., Dulak J. Heme oxygenase-1 in tumors: is it a false friend?. Antioxid. Redox Signal 2007, 9:2099-2117.